Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16126885 | 0.69 | — | — | |
| SCHEMBL15426833 | 0.68 | MAPT (0.37) | — | |
| SCHEMBL15358775 | 0.64 | ADORA2A (0.33) | ADORA2AADORA1CDK1 | |
| SCHEMBL21949053 | 0.63 | — | — | |
| SCHEMBL5490092 | 0.62 | — | — | |
| Hydrochloric Acid SCHEMBL29208961 | 0.59 | — | — | |
| SCHEMBL21245431 | 0.59 | — | — | |
| SCHEMBL19142284 | 0.59 | — | — | |
| SCHEMBL13978861 | 0.58 | GAA (0.53) | — | |
| SCHEMBL21467540 | 0.57 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434763-B2 | Derivatives of pyridinone as inhibitors for tissue transglutaminase | ZEDIRA GMBH (DE) | 2016-09-06 | — | — | US | disclosed |
| US-9242937-B2 | Pharmaceutically active disubstituted pyridine derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-01-26 | — | — | US | disclosed |
| US-20150329537-A2 | CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA | LEADDISCOVERY CENTER GMBH (DE) | 2015-11-19 | — | — | US | disclosed |
| US-20150203535-A1 | DERIVATIVES OF PYRIDINONE AS INHIBITORS FOR TISSUE TRANSGLUTAMINASE | ZEDIRA GMBH (DE) | 2015-07-23 | — | — | US | disclosed |
| US-8999982-B2 | Pharmaceutically active compounds as Axl inhibitors | LEAD DISCOVERY CENTER GMBH (DE) | 2015-04-07 | — | — | US | disclosed |
| US-20140296304-A1 | Pharmaceutically Active Disubstituted Pyridine Derivatives | LEAD DISCOVERY CENTER GMBH (DE) | 2014-10-02 | — | — | US | disclosed |
| US-20140287454-A1 | SUSCEPTIBILITY TO SELECTIVE CDK9 INHIBITORS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2014-09-25 | — | — | US | disclosed |
| US-20140018365-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCCHAFTEN E.V. (DE) | 2014-01-16 | — | — | US | disclosed |
| US-20130079345-A1 | PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203535-A1 | DERIVATIVES OF PYRIDINONE AS INHIBITORS FOR TISSUE TRANSGLUTAMINASE | PLPBP, PNPO, PDXK | ADORA2A 2522/4885ADORA1 2010/4885CDK1 441/4885 |
| US-20130079345-A1 | PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES | PDE5A, TESK2, PAK5 | ADORA2A 986/4885ADORA1 1938/4885CDK1 384/4885 |
| US-20140296304-A1 | Pharmaceutically Active Disubstituted Pyridine Derivatives | PINK1, PDPK1, LCK | ADORA2A 1104/4885ADORA1 1334/4885CDK1 199/4885 |
| US-20150329537-A2 | CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA | CDK9, CDK19, CDKN1A | ADORA2A 4465/4885ADORA1 4436/4885CDK1 4/4885 |
| US-20140018365-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | AXL, FLT3, ERBB3 | ADORA2A 603/4885ADORA1 728/4885CDK1 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.